PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial.

Trial Profile

PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Accrual to date is 15%, according to United Kingdom Clinical Research Network record.
    • 24 Sep 2012 Long-term follow-up results in 1256 patients published in the Journal of Clinical Oncology.
    • 07 Jun 2011 Long-term follow-up results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top